Robert is currently the Group Vice President of the CDDA, China & Japan Medical, a component of Lilly Research Laboratories and Medical Affairs. In this role, Robert has responsibility for worldwide delivery of clinical research across all therapeutic areas as well as Medical Affairs in both China and Japan. After completing his Ph.D. in Pharmacology and Toxicology at Queen’s University in Canada, Robert joined Eli Lilly Canada in the Regulatory Affairs organization where he led successful approval efforts, for neuroscience and anti-infective new chemical entities. Robert has held a number of leadership roles in Regulatory Affairs, Project Management, Quality, and Health Outcomes in Canada, the US, and Japan. In 2005, Robert was named Executive Director, Global Patient Safety, and in 2009 was named Vice President, Global Ethics and Compliance where he had responsibility for providing Ethics and Compliance leadership to functional and geographic areas across Eli Lilly. Robert returned to Lilly Research Laboratories as Vice President Global Regulatory Affairs-North America, with responsibility for leading Lilly’s interactions with the FDA, including submissions, review, and approvals, as well as representing industry in engagement with the FDA on key policy topics, including negotiation of user fee agreements (specifically PDUFA VI). In 2017, Robert assumed responsibility for Global Clinical Development. In 2020, Robert was promoted to his current position as Group Vice President, CDDA, China & Japan Medical.